Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia. Issue 3 (March 2023)

• Record Type: Journal Article
• Authors: He, Xiaoyan; Huang, Wanting; Wan, Xiong; Li, Xiaoya; Chang, Qiuhong; Ding, Ling
• Is Part Of: Journal of international medical research. Volume 51:Issue 3(2023)
• Publication Date: 2023-03
• Subjects: Piperacillin -- cefoperazone -- tazobactam -- sulbactam -- cross-reaction -- thrombocytopenia; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/03000605231162434
• Languages: English
• ISSNs: 0300-0605

Abstract

Beta-lactam antibiotics commonly cause immune thrombocytopenia. Cross-reactivity in patients with drug-induced immune thrombocytopenia has rarely been reported. In this study, we describe the case of a 79-year-old man who developed thrombocytopenia after receiving piperacillin–tazobactam for an acute exacerbation of chronic obstructive pulmonary disease, and he was successfully treated with meropenem and cefotiam. However, thrombocytopenia recurred after cefoperazone–sulbactam administration. This indicated that cross-reactivity of platelet-specific antibodies occurred between piperacillin–tazobactam and cefoperazone–sulbactam. However, the responsible drug structures remain unknown, requiring further investigation. Likewise, chemical structure similarities among beta-lactam antibiotics must be examined to determine the risk of immune thrombocytopenia in the clinical setting.